Clinical pharmacologic markers and endpoints are more relevant to bioequivalence assessment than pharmacokinetic measures for certain drugs and biologics. This can be true for drugs that are delivered to the site of action after parenteral or oral delivery as well as for nonabsorbable or locally delivered drugs and biologics. Pharmacologic measures will be more important as biotechnology products and gene therapy products come off patent.
WagnerJG. Kinetics of pharmacologic response I: Proposed relationships between response and drug concentration in the intact animal. J Theoret Biol.1968;20:173–201.
2.
HolfordNHGSheinerLB. Kinetics of Pharmacologic Response. Pharmacol Ther.1982;16: 143–166.
3.
ColburnWAEldonMA. Models of Drug Action: Experimental Design Issues. In: Van BoxtelCJHolfordNHGDanhofM, Eds. The In Vivo Study of Drug Action.Amsterdam, The Netherlands: Elsevier; 1992:17–29.
4.
ColburnWA. Drugs and Endogenous Ligands Compete for Receptor Occupancy. J Clin Pharmacol.1994;34:1148–1152.
5.
ColburnWABrazzellRKHolazoAA. Verapamil Pharmacodynamics Following IV and Oral Administration: Theoretical Considerations. J Clin Pharmacol.1986;26:71–73.
6.
KleinbloesemCHvan BrummelenPDanhofMFaberHUrquhartJBreimerDD. Rate of Increase in the Plasma Concentrations of Nifedipine as a Major Determinant of it's Hemodynamic Effects in Humans. Clin Pharmacol Ther.1987;41:26–30.
7.
ErmerJCHicksDRWheelerSCKramelMJuskoWJ. Concomitant Etodolac Affects Neither the Unbound Clearance Nor the Pharmacologic Effect of Warfarin. Clin Pharmacol Ther.1994;55:305–316.
8.
DoiSAR. Pharmacodynamic Optimization of Warfarin Therapy. Clin Pharmacol Ther.1994;55:597–601.
9.
ChanEMcLachlanAO'ReillyRRowlandM.Stereochemical Aspects of Warfarin Drug Interactions: Use of a Combined Pharmacokinetic-Pharmacodynamic Model. Clin Pharmacol Ther.1994;56:286–294.
10.
ColburnWA. Peptide, Peptoid and Protein Pharmacokinetics/Pharmacodynamics. In: GarzonePDColburnWAMokotoffM, Eds. Pharmacokinetics and Pharmacodynamics, Vol. 3. Cincinatti, Ohio: Harvey Whitney Books; 1991: 94–115.
11.
WillsRJ. A Kinetic/Dynamic Perspective of a Peptide and a Protein: GRF and rHuIFN-α-2a. In: GarzonePDColburnWAMokotoffM, Eds. Pharmacokinetics and Pharmacodynamics, Vol. 3. Cincinatti, Ohio: Harvey Whitney Books; 1991:117–127.
